Intellia Therapeutics (NTLA) is down -46.3%, or -$11.86 to $13.74.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics: Buy Rating Affirmed Amid Phase 3 Trial Pause and Long-term Confidence
- Intellia Therapeutics: Buy Rating Affirmed Amid Strategic Developments and CRISPR-Cas9 Potential
- Mitchell Kapoor Maintains Buy Rating on Intellia Therapeutics Despite Market Overreaction to Phase 3 Trial Pause
- Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright
- Leerink not surprised Intellia underperforming following trial update